Advertisement

Topics

US FDA’s co-crystal final guidance to reduce cGMP burden

06:25 EST 15 Feb 2018 | in-PharmaTechnologis

In response to stakeholder feedback, the US FDA has issued a final guidance detailing changes to the regulatory classification of co-crystals, from intermediate to API.

Original Article: US FDA’s co-crystal final guidance to reduce cGMP burden

NEXT ARTICLE

More From BioPortfolio on "US FDA’s co-crystal final guidance to reduce cGMP burden"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...